Showing results 1 to 20 of 154
next >
| Issue Date | Title | Author(s) |
| 2012 | 3D object surface meshing based on occupancy grids | Xu, Jie; Zha, Hongbin |
| 2012 | 3D pose estimation for bin-picking task using convex hull | Xu, Jie; Pu, Songtao; Zeng, Gang; Zha, Hongbin |
| May-2025 | An accurate and trustworthy deep learning approach for bladder tumor segmentation with uncertainty estimation | Xu, Jie; Wang, Haixin; Lu, Min; Bi, Hai; Li, Deng; Xue, Zixuan; Zhang, Qi |
| 2019 | Activation of Aurora A kinase increases YAP stability via blockage of autophagy | Wang, Peng; Gong, Ying; Guo, Tao; Li, Man; Fang, Lei; Yin, Shengchen; Kamran, Muhammad; Liu, Yang; Xu, Jie; Xu, Lingzhi; Peng, Fei; Xue, Xiaoyuan; Yang, Mengying; Hung, Mie-Chie; Lam, Eric W-F; Gu, Chundong; Wang, Chunli; Zhan, Qimin; Liu, Quentin |
| 2014 | Acute Insulin Resistance Mediated by Advanced Glycation Endproducts in Severely Burned Rats | Zhang, Xing; Xu, Jie; Cai, Xiaoqing; Ji, Lele; Li, Jia; Cao, Bing; Li, Jun; Hu, Dahai; Li, Yan; Wang, Haichang; Xiong, Lize; Xiao, Ruiping; Gao, Feng |
| 18-Feb-2021 | Adoption of Electronic Health Records (EHRs) in China During the Past 10 Years: Consecutive Survey Data Analysis and Comparison of Sino-American Challenges and Experiences | Liang, Jun; Li, Ying; Zhang, Zhongan; Shen, Dongxia; Xu, Jie; Zheng, Xu; Wang, Tong; Tang, Buzhou; Lei, Jianbo; Zhang, Jiajie |
| 2-Jun-2021 | Air pollutants and outpatient visits for influenza-like illness in Beijing, China | Li, Xiaoguang; Xu, Jie; Wang, Wei; Liang, Jing-Jin; Deng, Zhong-Hua; Du, Juan; Xie, Ming-Zhu; Wang, Xin-Rui; Liu, Yaqiong; Cui, Fuqiang; Lu, Qing-Bin |
| 1-Apr-2022 | An air-stable iron/manganese-based phosphate cathode for high performance sodium-ion batteries | Wang, Ning; Ma, Jiachen; Liu, Zhaolu; Xu, Jie; Zhao, Deqiang; Wang, Nan; Yang, Chen; Cao, Yongjie; Lu, Jing; Zhang, Junxi |
| 1-Jun-2023 | ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study | Shen, Jingnan; Guo, Wei; Wang, Jin; Xie, Xianbiao; Xie, Lu; Xu, Jie; Jing, Chen; Lin, Jianhua; Li, Xianan; Zhou, Yong; Wang, Guowen; Zhang, Xiaojing; Yao, Weitao; Dong, Yang; Ye, Zhaoming; Wang, Li; Zeng, Yanyan; Wu, Yongyong; Yang, Xiugao; Zhang, Yanfeng |
| 2019 | Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517). | Xu, Jie; Xie, Lu; Guo, Wei; Tang, Xiaodong; Yang, Rongli; Yan, Taiqiang; Liu, Kuisheng; Gu, Jin |
| Mar-2021 | Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial | Xu, Jie; Xie, Lu; Sun, Xin; Liu, Kuisheng; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Guo, Wei; Gu, Jin |
| 2020 | Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma | Xie, Lu; Xu, Jie; Sun, Xin; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Guo, Wei |
| 2016 | Anti-inflammatory activities of fenoterol through beta-arrestin-2 and inhibition of AMPK and NF-kappa B activation in AICAR-induced THP-1 cells | Wang, Wei; Chen, Jing; Li, Xiao Guang; Xu, Jie |
| 1-Jun-2024 | Apatinib combined with ifosfamide and etoposide versus ifosfamide and etoposide in relapsed or refractory osteosarcoma (OAIE/PKUPH-sarcoma 11): A multicenter, randomized controlled trial | Xie, Lu; Xu, Jie; Sun, Xin; Liang, Xin; Liu, Kuisheng; Sun, Kunkun; Li, Yuan; Liu, Rong; Wang, Du; Shao, Shurong; Li, Peiyu; Pang, Zheng; Zhou, Guangxin; Wu, Sujia; Hua, Yingqi; Hu, Haiyan; Yang, Yi; Ji, Tao; Guo, Wei; Tang, Xiaodong |
| 2018 | Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: An open label phase 2 clinical trial. | Xie, Lu; Xu, Jie; Sun, Xin; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Guo, Wei |
| 2019 | Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial | Xie, Lu; Xu, Jie; Sun, Xin; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Guo, Wei |
| 2018 | Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China | Xie, Lu; Guo, Wei; Wang, Ye; Yan, Taiqiang; Ji, Tao; Xu, Jie |
| 2020 | Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study | Xie, Lu; Xu, Jie; Sun, Xin; Liu, Kuisheng; Li, Xiaowei; He, Fangzhou; Liu, Xinyu; Gu, Jin; Lv, Zhe; Yang, Rongli; Tang, Xiaodong; Yan, Taiqiang; Li, Dasen; Yang, Yi; Dong, Sen; Sun, Kunkun; Shen, Danhua; Guo, Wei |
| 2020 | Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial | Xie, Lu; Xu, Jie; Sun, Xin; Guo, Wei; Gu, Jin; Liu, Kuisheng; Zheng, Bingxin; Ren, Tingting; Huang, Yi; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Sun, Kunkun; Shen, Danhua; Li, Yuan |
| 2019 | Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A prospective, open label, phase II trial. | Xie, Lu; Guo, Wei; Xu, Jie; Sun, Xin; Liu, Kuisheng; Zheng, Bingxin; Ren, Ting; Huang, Yi; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Sun, Kunkun; Shen, Danhua; Li, Yuan |
